Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

31.33 +1.60 (+5.38%)
Streaming Delayed Price Updated: 1:40 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
The company will pay CordenPharma $150 million over three years in a manufacturing deal. 
Via Investor's Business Daily
Is Eli Lilly Stock a Buy?
Via The Motley Fool
The State of Weight Loss Drugs
Via The Motley Fool
Is Viking Therapeutics a Buy Right Now?
Via The Motley Fool
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Stocks to Buy With Less Than $40
Via The Motley Fool
BJ's Wholesale Club Posts Better-Than-Expected Earnings, Joins Burlington Stores, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
MarketBeat Week in Review – 02/24 - 02/28
Stocks tried to stage a weak rally to close the week but the short-term outlook will continue to be dictated by the uncertainty that is creating volatility 
Via MarketBeat
Topics Economy World Trade
Exposures Interest Rates Tariff
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Via The Motley Fool
2 Stocks That Could Soar Again in 2025
Via The Motley Fool
Has the Bubble Burst for Viking Therapeutics Stock?
Via The Motley Fool
Earnings Scheduled For February 5, 2025
Via Benzinga
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Exposures Product Safety
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Via The Motley Fool
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Via The Motley Fool
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year
In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity. 
Via Stocktwits
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings!
Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum. 
Via Talk Markets
Topics Stocks / Equities
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates
Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics. 
Via The Motley Fool
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'
First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback